107, Ihyeon-ro 30beon-gil
Giheung-gu
Yongin-Si
South Korea
82 3 1260 9300
https://www.globalgreencross.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Il-Sup Huh Ph.D. | Chairman & CEO | N/A | N/A | 1954 |
Mr. Eun-Cheol Hur | President & Director | N/A | N/A | 1972 |
Mr. Min-Taek Lee | Senior Managing Director of Sales | N/A | N/A | 1963 |
Mr. Young Sup Huh | Executive Vice President | N/A | N/A | 1941 |
Mr. In-Jae Lee | Senior MD & Director | N/A | N/A | 1963 |
Mr. Byeong-Hwa Kim | VP & Director | N/A | N/A | 1958 |
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for hereditary antithrombin-III deficiency; Facnyne inj. for hemophilia B; Fibrinogen to treat hypofibrinogenemia and afibrinogenemia; Gamma Globulin for hypogammaglobulinemia and agammaglobulinemia; GCFLU Quadrivalent and GC FLU pre-filled syringe inj. for prevention of influenza; GreenGene F inj. for bleeding symptom control and hemostasis for persons with hemophilia A; GreenGene inj. for bleeding episodes induced by hemophilia A; Greenplast Q for sealing tissues and closing open wounds; and Green-VIII inj. for Hemophilia A with supplies of blood coagulation factor VIII. In addition, it provides Hepabig inj. for hepatitis B; Histobulin to treat bronchial asthma; Hunterase for hunter syndrome; I.V. Hepabig inj. for prevention of hepatitis B recurrence in patients following liver transplantation; I.V.-Globulin SN inj. 5%; Immuncell-LC to treat liver cancer; Sero-Tet inj. for prophylaxis of tetanus and the reduction of tetanus symptoms; Shinbaro for anti-inflammation, pain relief, and osteoarthritis; Varicella Vaccine-GCC inj. for prophylaxis of varicella; and Varicella-Zoster Immune Globulin-GCC inj. for passive immunity to susceptible immunodeficient children exposed to varicella. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea. GC Biopharma Corp. is a subsidiary of Green Cross Holdings Corporation.
GC Biopharma Corp.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder rights: 8; Compensation: 9.